Clinical Trial Update: R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating R-CVP for non-conjunctival ocular adnexal MALT lymphoma (OAML) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-conjunctival Ocular Adnexal Malt Lymphoma

Drugs mentioned

• R-CVP (rituximab, cyclophosphamide, vincristine, prednisone)

Snippet

Sponsor: Konkuk University Medical Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED